Satralizumab (Genetical Recombination)



Satralizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from a mouse anti-human interleukin-6 receptor monoclonal antibody, human framework regions and human IgG2 constant regions. In the H-chain, the amino acid residues at position 133, 135, 139, 140, 221, 266, 353, 417 and 432 are substituted by Ser, Lys, Gly, Gly, Ser, Gln, Gln, Glu and Ala, respectively, and Gly and Lys at the C-terminus are deleted. Satralizumab is produced in Chinese hamster ovary cells. Satralizumab is a glycoprotein (molecular weight: ca. 146,000) composed of 2 H-chains (γ2-chains) consisting of 443 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1535963-91-7]